Al-Mehdi: Rx of IBD Flashcards
pathogenesis behind IBD summed up
loss of tolerance of mucosal immune system leading to attack of one’s own microbiota
how are naiive Th0 (CD4) T cells activated
dendritic cells present antigen
co-stimulation from CD80/86 binding to CD28
activation of T cell allows for what to be produced and what effect
IL-2; clonal expansion of T cells
normally, _____ takes off phosphate group of NFAT when influx of Ca2+ binds to calmodulin in T cell
calcineurin
what happens when IL-2 autocrine signaling happens in T cell
activates mTOR, cytokines produced, clonal expansion of cells
cytokine that activates Th1 cell
IL-12
T cell that activates macrophages and CD8+ T cells
Th1
cytokines that activate Th17 T cell
IL-1, 6, 23
this T cell attracts neutrophils to infection site
Th17
T cells involved in Crohn’s disease
Th1 and Th17
cytokines that activate Th2 T cell
IL-4, IL-25
cytokine that Th2 cell makes that activates eosinophils
IL-5
cytokine that Th2 cell makes that activates mast cells
IL-9
cytokines from Th2 T cell involved in elimination of helminths, atopy, eosinophilic esophagitis
IL-5 and IL-9
T cell involved in Ulcerative colitis
Th2
cytokine that activates Treg cell
IFN-a
T cell that produces IL-10 and TGF-b to prevent autoimmune disease and inflammation
Treg
cytokines that activate Tfh (T follicular helper cell)
IL-4, IL-21
T cell that produces IL-21 that activates B cells
Tfh (T follicular helper) cell
Which T cell and which cytokines reduce inflammation and disease severity in autoimmune diseases?
Treg; IL-10 and TGF-beta
drugs that block lymphocyte egress from lymph nodes and peyer’s patches (used for UC)
OZANIMOD
FINGOLIMOD
(-IMODs)
these drugs are irreversible agonists of sphingosine-1-phosphate receptor (block lymphocyte egress)
OZANIMOD
FINGOLIMOD
drugs used for UC and CD that block lymphocyte transmigration out of endothelium and their MoA
VEDOLIZUMAB
ETROLIZUMAB
(-LIZUMABs)
MoA: anti-a4b7 in the gut
integrin on lymphocyte that VEDOLIZUMAB and ETROLIZUMAB block
a4b7
on EC of gut that a4b7 bind to
MAdCAM
anti-a4b7 and anti-a4b1 MoA (blocks lymphocyte transmigration out of endothelium)
NATALIZUMAB
drug that can cause progressive multifocal leukoencephalopathy (PML) due to binding of a4b1 that is found on EC everywhere in body
NATALIZUMAB
used for CD and MS that has SE of PML
NATALIZUMAB
drugs that block mucosal cytokine release and used for UC
SULFASALAZINE
MESALAMINE
OLSALAZINE
BALSALAZIDE
drugs used for UC that have anti-inflammatory effect and block mucosal cytokine release
MESALAMINE
OLSALAZINE
BALSALAZIDE
SULFASALAZINE